• Product nameAnti-CSRP3 antibody
    See all CSRP3 primary antibodies
  • Description
    Rabbit polyclonal to CSRP3
  • SpecificityThis antibody is specific for CSRP3.
  • Tested applicationsSuitable for: WB, ELISA, ICC/IF, IHC-Pmore details
  • Species reactivity
    Reacts with: Rat, Human
    Predicted to work with: Mouse, Cow, Dog, Pig
  • Immunogen

    A region within synthetic peptide: QGAGCLSTDT GEHLGLQFQQ SPKPARSVTT SNPSKFTAKF GESEKCPRCG, corresponding to amino acids 75-124 of Human CSRP3

  • Positive control
    • Jurkat cell lysate This antibody gave a positive result in IHC in the following FFPE tissue: Human normal heart muscle.


Associated products


Our Abpromise guarantee covers the use of ab42504 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 0.125 µg/ml. Predicted molecular weight: 21 kDa. Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.
ELISA 1/12500.
ICC/IF Use at an assay dependent concentration.
IHC-P Use a concentration of 1 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.


  • FunctionPositive regulator of myogenesis. Plays a crucial and specific role in the organization of cytosolic structures in cardiomyocytes. Could play a role in mechanical stretch sensing. May be a scaffold protein that promotes the assembly of interacting proteins at Z-line structures. It is essential for calcineurin anchorage to the Z line. Required for stress-induced calcineurin-NFAT activation.
  • Tissue specificityCardiac and slow-twitch skeletal muscles.
  • Involvement in diseaseDefects in CSRP3 are the cause of cardiomyopathy dilated type 1M (CMD1M) [MIM:607482]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
    Defects in CSRP3 are the cause of cardiomyopathy familial hypertrophic type 12 (CMH12) [MIM:612124]. Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
  • Sequence similaritiesContains 2 LIM zinc-binding domains.
  • Cellular localizationNucleus. Cytoplasm. Cytoplasm > cytoskeleton. Cytoplasm > myofibril > sarcomere > Z line. Mainly cytoplasmic (By similarity). In the nucleus it associates with the actin cytoskeleton (Potential). In the Z line, found associated with GLRX3.
  • Information by UniProt
  • Database links
  • Alternative names
    • cardiac antibody
    • Cardiac LIM protein antibody
    • CLP antibody
    • CMD1M antibody
    • CMH12 antibody
    • CRP3 antibody
    • Csrp3 antibody
    • CSRP3_HUMAN antibody
    • Cysteine and glycine-rich protein 3 antibody
    • Cysteine rich protein 3 antibody
    • Cysteine-rich protein 3 antibody
    • LIM domain only 4 antibody
    • LIM domain protein antibody
    • LMO4 antibody
    • MLP antibody
    • Muscle LIM protein antibody
    see all

Anti-CSRP3 antibody images

  • IHC image of CSRP3 staining in Human normal heart muscle formalin fixed paraffin embedded tissue section, performed on a Leica Bond™ system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab42504, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.


    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

  • ab42504 staining CSRP3 in Rat neonatal cardiac myocyte cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with paraformaldehyde and blocked with 1% BSA for 60 minutes at 21°C. Samples were incubated with primary antibody (1/100 in PBS + 1% BSA) for 16 hours at 4°C. An Alexa Fluor®488-conjugated Donkey anti-rabbit IgG polyclonal(1/500) was used as the secondary antibody.

    See Abreview

  • Anti-CSRP3 antibody (ab42504) at 0.125 µg/ml + Jurkat cell lysate

    HRP conjugated anti-Rabbit IgG at 1/50000 dilution

    Predicted band size : 21 kDa

References for Anti-CSRP3 antibody (ab42504)

This product has been referenced in:
  • Roberts MD  et al. Early depression of Ankrd2 and Csrp3 mRNAs in the polyribosomal and whole tissue fractions in skeletal muscle with decreased voluntary running. J Appl Physiol 112:1291-9 (2012). WB ; Rat . Read more (PubMed: 22282489) »

See 1 Publication for this product

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunocytochemistry/ Immunofluorescence
Sample Rat Cell (Neonatal cardiac myocytes)
Specification Neonatal cardiac myocytes
Fixative Paraformaldehyde
Permeabilization No
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: RT°C

Abcam user community

Verified customer

Submitted Apr 26 2013

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Rat Cell lysate - whole cell (Cardiac myocytes)
Loading amount 10 µg
Specification Cardiac myocytes
Gel Running Conditions Reduced Denaturing (10 % gel)
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: RT°C

Abcam user community

Verified customer

Submitted Apr 15 2013